Efsitora alfa
Once-weekly basal insulin Fc analog · insulin class · sc weekly · Eli Lilly
Top dose
titrated
HbA1c reduction
-1.34%
at week 52 · treatment policy
AE discontinuation
2.0%
Status
phase 3
Pivotal trial
- Trial
- QWINT-2
- Indication
- type 2 diabetes (insulin-naive)
- Duration
- 52 weeks
- ClinicalTrials.gov
- NCT05362058
- Sponsor
- Eli Lilly
Notes
QWINT-2 (2024): once-weekly insulin efsitora alfa HbA1c -1.34% vs daily degludec -1.26% in insulin-naive T2D at week 52, non-inferiority met. Lilly's once-weekly basal challenger to icodec. Hypoglycemia, not AE-led discontinuation, is the key safety read.